VBI Vaccines (NASDAQ:VBIV) Stock Crosses Above 50 Day Moving Average of $0.61

VBI Vaccines Inc. (NASDAQ:VBIVGet Free Report)’s stock price passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.61 and traded as high as $0.63. VBI Vaccines shares last traded at $0.62, with a volume of 171,407 shares traded.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on VBI Vaccines in a research note on Tuesday. They set a “sell” rating on the stock.

View Our Latest Research Report on VBI Vaccines

VBI Vaccines Trading Up 2.6 %

The firm has a 50-day simple moving average of $0.61 and a two-hundred day simple moving average of $0.62. The company has a market capitalization of $14.64 million, a price-to-earnings ratio of -0.05 and a beta of 1.93.

Institutional Investors Weigh In On VBI Vaccines

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP acquired a new stake in VBI Vaccines during the 1st quarter worth about $26,000. Point72 Hong Kong Ltd acquired a new stake in shares of VBI Vaccines during the 2nd quarter valued at about $29,000. Barclays PLC grew its position in shares of VBI Vaccines by 89.9% during the 1st quarter. Barclays PLC now owns 98,337 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 46,566 shares during the period. Voya Investment Management LLC grew its position in shares of VBI Vaccines by 29.7% during the 4th quarter. Voya Investment Management LLC now owns 95,428 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 21,824 shares during the period. Finally, BNP Paribas Arbitrage SA grew its position in shares of VBI Vaccines by 208.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 47,668 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 32,227 shares during the period. 12.26% of the stock is owned by institutional investors and hedge funds.

VBI Vaccines Company Profile

(Get Free Report)

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.

Recommended Stories

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.